Investigational AMG 212 Shows Anti-cancer Activity in Advanced mCRPC in Phase 1 Trial

Investigational AMG 212 Shows Anti-cancer Activity in Advanced mCRPC in Phase 1 Trial
Amgen’s investigational therapy AMG 212 (pasotuxizumab) is safe, and showing therapeutic activity against metastatic castration-resistant prostate cancer (mCRPC) in a Phase 1 clinical trial, data show. This is the first study suggesting that Amgen’s BiTE immunotherapy, designed to bring together patients’ immune T-cells and cancer cells, “can be efficacious in solid tumors,” the researchers said. The findings were discussed at the recent 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, in Chicago, in the poster “Phase 1 Study of Pasotuxizumab (BAY 2010112), a PSMA-targeting BiTE (Bispecific T Cell Engager) Immunotherapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC).” The company’s proprietary BiTE technology platform builds antibodies that target two proteins at the same time — one in cancer cells and the other in immune cells. Specifically, AMG 212 targets the prostate-specific membrane antigen (PSMA) in prostate cancer cells and the CD3 protein at the surface of T-cells. This forms a bridge between T-cells and tumor cells, helping the T-cells kill the tumor. The safety and early anti-cancer activity of AMG 212 was evaluated in a Phas
Subscribe or to access all post and page content.